Analysis of peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis (MS) patients 1 day before, 1 day after, and up to 12 months after the initiation of interferon beta-1a (IFN-beta-1a) therapy. Results identify biomarkers for beta-IFN responsiveness.